1-20 of 23
Marileila Varella-Garcia
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non–small Cell Lung Cancer

Free
Caroline E. McCoach, Anh T. Le, Katherine Gowan, Kenneth Jones, Laura Schubert, Andrea Doak, Adriana Estrada-Bernal, Kurtis D. Davies, Daniel T. Merrick, Paul A. Bunn, Jr, W. Tom Purcell, Rafal Dziadziuszko, Marileila Varella-Garcia, Dara L. Aisner, D. Ross Camidge, Robert C. Doebele
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (14): 3334–3347.
https://doi.org/10.1158/1078-0432.CCR-17-2452
Published: 15 July 2018
View articletitled, Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non–small Cell Lung Cancer
Open the PDF for Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non–small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Salivary Gland Cancer Patient-Derived Xenografts Enable Characterization of Cancer Stem Cells and New Gene Events Associated with Tumor Progression

Free
Stephen B. Keysar, Justin R. Eagles, Bettina Miller, Brian C. Jackson, Farshad N. Chowdhury, Julie Reisinger, Tugs-Saikhan Chimed, Phuong N. Le, John J. Morton, Hilary L. Somerset, Marileila Varella-Garcia, Aik-Choon Tan, John I. Song, Daniel W. Bowles, Mary E. Reyland, Antonio Jimeno
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (12): 2935–2943.
https://doi.org/10.1158/1078-0432.CCR-17-3871
Published: 14 June 2018
View articletitled, Salivary Gland Cancer Patient-Derived Xenografts Enable Characterization of Cancer Stem Cells and New Gene Events Associated with Tumor Progression
Open the PDF for Salivary Gland Cancer Patient-Derived Xenografts Enable Characterization of Cancer Stem Cells and New Gene Events Associated with Tumor Progression in another window
Includes: Supplementary data
Journal Articles

MET–GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors

Free
Matthew A. Smith, Thomas Licata, Aliya Lakhani, Marileila Varella Garcia, Hans-Ulrich Schildhaus, Vincent Vuaroqueaux, Balazs Halmos, Alain C. Borczuk, Y. Ann Chen, Benjamin C. Creelan, Theresa A. Boyle, Eric B. Haura
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (22): 7084–7096.
https://doi.org/10.1158/1078-0432.CCR-16-3006
Published: 14 November 2017
View articletitled, MET–GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors
Open the PDF for MET–GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors in another window
Includes: Supplementary data
Journal Articles

Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape

Free
Zixing Wang, Tae Beom Kim, Bo Peng, Jose Karam, Chad Creighton, Aron Joon, Fumi Kawakami, Patricia Trevisan, Eric Jonasch, Chi-Wan Chow, Jaime Rodriguez Canales, Pheroze Tamboli, Nizar Tannir, Christopher Wood, Federico Monzon, Keith Baggerly, Marileila Varella-Garcia, Bogdan Czerniak, Ignacio Wistuba, Gordon Mills, Kenna Shaw, Ken Chen, Kanishka Sircar
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (21): 6686–6696.
https://doi.org/10.1158/1078-0432.CCR-17-1057
Published: 31 October 2017
View articletitled, Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape
Open the PDF for Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape in another window
Includes: Supplementary data
Journal Articles

Oncogene mutations and translocations as molecular biomarkers and targets in advanced lung adenocarcinomas

Free
Paul A. Bunn, Mark Kris, Bruce Johnson, John Minna, David Kwiatkovski, John Iafrate, Ignacio Wistuba, Wilbur Wistuba, Marileila Varella-Garcia
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (19_Supplement): PL8-2.
https://doi.org/10.1158/DIAG-10-PL8-2
Published: 15 August 2014
View articletitled, Oncogene mutations and translocations as molecular biomarkers and targets in advanced lung adenocarcinomas
Journal Articles

Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies

Free
Daniel W. Bowles, Jennifer R. Diamond, Elaine T. Lam, Colin D. Weekes, David P. Astling, Ryan T. Anderson, Stephen Leong, Lia Gore, Marileila Varella-Garcia, Brian W. Vogler, Stephen B. Keysar, Elizabeth Freas, Dara L. Aisner, Chen Ren, Aik-Chook Tan, Francois Wilhelm, Manoj Maniar, S. Gail Eckhardt, Wells A. Messersmith, Antonio Jimeno
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (6): 1656–1665.
https://doi.org/10.1158/1078-0432.CCR-13-2506
Published: 13 March 2014
View articletitled, Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies
Open the PDF for Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies in another window
Includes: Supplementary data
Journal Articles

Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models

Free
Jennifer R. Diamond, S. Gail Eckhardt, Aik Choon Tan, Timothy P. Newton, Heather M. Selby, Kelsey L. Brunkow, Maria I. Kachaeva, Marileila Varella-Garcia, Todd M. Pitts, Mark R. Bray, Graham C. Fletcher, John J. Tentler
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (1): 291–303.
https://doi.org/10.1158/1078-0432.CCR-12-1611
Published: 02 January 2013
View articletitled, Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models
Open the PDF for Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models in another window
Includes: Supplementary data
Journal Articles

Diphtheria Toxin–Epidermal Growth Factor Fusion Protein DAB389EGF for the Treatment of Bladder Cancer

Free
Xiaoping Yang, Elizabeth Kessler, Lih-Jen Su, Andrew Thorburn, Arthur E. Frankel, Yuan Li, Francisco G. La Rosa, Jingping Shen, Chuan-Yuan Li, Marileila Varella-Garcia, L. Michael Glodé, Thomas W. Flaig
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (1): 148–157.
https://doi.org/10.1158/1078-0432.CCR-12-1258
Published: 02 January 2013
View articletitled, Diphtheria Toxin–Epidermal Growth Factor Fusion Protein DAB389EGF for the Treatment of Bladder Cancer
Open the PDF for Diphtheria Toxin–Epidermal Growth Factor Fusion Protein DAB389EGF for the Treatment of Bladder Cancer in another window
Journal Articles

Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer

Free
Kurtis D. Davies, Anh T. Le, Mariana F. Theodoro, Margaret C. Skokan, Dara L. Aisner, Eamon M. Berge, Luigi M. Terracciano, Federico Cappuzzo, Matteo Incarbone, Massimo Roncalli, Marco Alloisio, Armando Santoro, D. Ross Camidge, Marileila Varella-Garcia, Robert C. Doebele
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (17): 4570–4579.
https://doi.org/10.1158/1078-0432.CCR-12-0550
Published: 30 August 2012
View articletitled, Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer
Open the PDF for Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Common PIK3CA Mutants and a Novel 3′ UTR Mutation Are Associated with Increased Sensitivity to Saracatinib

Free
John J. Arcaroli, Kevin S. Quackenbush, Rebecca W. Powell, Todd M. Pitts, Anna Spreafico, Marileila Varella-Garcia, Lynne Bemis, Aik Choon Tan, Jaclyn M. Reinemann, Basel M. Touban, Arvind Dasari, S. Gail Eckhardt, Wells A. Messersmith
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (9): 2704–2714.
https://doi.org/10.1158/1078-0432.CCR-11-3167
Published: 30 April 2012
View articletitled, Common PIK3CA Mutants and a Novel 3′ UTR Mutation Are Associated with Increased Sensitivity to Saracatinib
Open the PDF for Common PIK3CA Mutants and a Novel 3′ UTR Mutation Are Associated with Increased Sensitivity to Saracatinib in another window
Includes: Supplementary data
Journal Articles

Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer

Free
Robert C. Doebele, Amanda B. Pilling, Dara L. Aisner, Tatiana G. Kutateladze, Anh T. Le, Andrew J. Weickhardt, Kimi L. Kondo, Derek J. Linderman, Lynn E. Heasley, Wilbur A. Franklin, Marileila Varella-Garcia, D. Ross Camidge
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (5): 1472–1482.
https://doi.org/10.1158/1078-0432.CCR-11-2906
Published: 01 March 2012
View articletitled, Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer
Open the PDF for Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Abnormalities of the TITF-1 Lineage-Specific Oncogene in NSCLC: Implications in Lung Cancer Pathogenesis and Prognosis

Free
Ximing Tang, Humam Kadara, Carmen Behrens, Diane D Liu, Yun Xiao, David Rice, Adi F. Gazdar, Junya Fujimoto, Cesar Moran, Marileila Varella-Garcia, J Jack Lee, Waun Ki Hong, Ignacio I. Wistuba
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (8): 2434–2443.
https://doi.org/10.1158/1078-0432.CCR-10-1412
Published: 14 April 2011
View articletitled, Abnormalities of the TITF-1 Lineage-Specific Oncogene in NSCLC: Implications in Lung Cancer Pathogenesis and Prognosis
Open the PDF for Abnormalities of the TITF-1 Lineage-Specific Oncogene in NSCLC: Implications in Lung Cancer Pathogenesis and Prognosis in another window
Includes: Supplementary data
Journal Articles

Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment

Free
D. Ross Camidge, Scott A. Kono, Antonella Flacco, Aik-Choon Tan, Robert C. Doebele, Qing Zhou, Lucio Crino, Wilbur A. Franklin, Marileila Varella-Garcia
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (22): 5581–5590.
https://doi.org/10.1158/1078-0432.CCR-10-0851
Published: 14 November 2010
View articletitled, Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment
Open the PDF for Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment in another window
Journal Articles

Gene Array and Fluorescence In situ Hybridization Biomarkers of Activity of Saracatinib (AZD0530), a Src Inhibitor, in a Preclinical Model of Colorectal Cancer

Free
John J. Arcaroli, Basel M. Touban, Aik Choon Tan, Marileila Varella-Garcia, Rebecca W. Powell, S. Gail Eckhardt, Paul Elvin, Dexiang Gao, Wells A. Messersmith
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (16): 4165–4177.
https://doi.org/10.1158/1078-0432.CCR-10-0066
Published: 11 August 2010
View articletitled, Gene Array and Fluorescence In situ Hybridization Biomarkers of Activity of Saracatinib (AZD0530), a Src Inhibitor, in a Preclinical Model of Colorectal Cancer
Open the PDF for Gene Array and Fluorescence In situ Hybridization Biomarkers of Activity of Saracatinib (AZD0530), a Src Inhibitor, in a Preclinical Model of Colorectal Cancer in another window
Journal Articles

Development of an Integrated Genomic Classifier for a Novel Agent in Colorectal Cancer: Approach to Individualized Therapy in Early Development

Free
Todd M. Pitts, Aik Choon Tan, Gillian N. Kulikowski, John J. Tentler, Amy M. Brown, Sara A. Flanigan, Stephen Leong, Christopher D. Coldren, Fred R. Hirsch, Marileila Varella-Garcia, Christopher Korch, S. Gail Eckhardt
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (12): 3193–3204.
https://doi.org/10.1158/1078-0432.CCR-09-3191
Published: 14 June 2010
View articletitled, Development of an Integrated Genomic Classifier for a Novel Agent in Colorectal Cancer: Approach to Individualized Therapy in Early Development
Open the PDF for Development of an Integrated Genomic Classifier for a Novel Agent in Colorectal Cancer: Approach to Individualized Therapy in Early Development in another window
Includes: Supplementary data
Journal Articles

HER Family Receptor Abnormalities in Lung Cancer Brain Metastases and Corresponding Primary Tumors

Free
Menghong Sun, Carmen Behrens, Lei Feng, Natalie Ozburn, Ximing Tang, Guosheng Yin, Ritsuko Komaki, Marileila Varella-Garcia, Waun Ki Hong, Kenneth D. Aldape, Ignacio I. Wistuba
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (15): 4829–4837.
https://doi.org/10.1158/1078-0432.CCR-08-2921
Published: 29 July 2009
View articletitled, HER Family Receptor Abnormalities in Lung Cancer Brain Metastases and Corresponding Primary Tumors
Open the PDF for HER Family Receptor Abnormalities in Lung Cancer Brain Metastases and Corresponding Primary Tumors in another window
Includes: Supplementary data
Journal Articles

Fluorescence In situ Hybridization Subgroup Analysis of TRIBUTE, a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non–Small Cell Lung Cancer

Free
Fred R. Hirsch, Marileila Varella-Garcia, Rafal Dziadziuszko, Yun Xiao, Sujatha Gajapathy, Margaret Skokan, Ming Lin, Vincent O'Neill, Paul A. Bunn, Jr.
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (19): 6317–6323.
https://doi.org/10.1158/1078-0432.CCR-08-0539
Published: 30 September 2008
View articletitled, Fluorescence In situ Hybridization Subgroup Analysis of TRIBUTE, a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non–Small Cell Lung Cancer
Open the PDF for Fluorescence In situ Hybridization Subgroup Analysis of TRIBUTE, a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non–Small Cell Lung Cancer in another window
Journal Articles

KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

Free
Erminia Massarelli, Marileila Varella-Garcia, Ximing Tang, Ana C. Xavier, Natalie C. Ozburn, Diane D. Liu, Benjamin N. Bekele, Roy S. Herbst, Ignacio I. Wistuba
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (10): 2890–2896.
https://doi.org/10.1158/1078-0432.CCR-06-3043
Published: 15 May 2007
View articletitled, KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer
Open the PDF for KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer in another window
Journal Articles

Antitumor Activity of the Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Gefitinib (ZD1839, Iressa) in Non–Small Cell Lung Cancer Cell Lines Correlates with Gene Copy Number and EGFR Mutations but not EGFR Protein Levels

Free
Barbara A. Helfrich, David Raben, Marileila Varella-Garcia, Dan Gustafson, Daniel C. Chan, Lynne Bemis, Chris Coldren, Anna Barón, Chan Zeng, Wilbur A. Franklin, Fred R. Hirsch, Adi Gazdar, John Minna, Paul A. Bunn, Jr.
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (23): 7117–7125.
https://doi.org/10.1158/1078-0432.CCR-06-0760
Published: 04 December 2006
View articletitled, Antitumor Activity of the Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Gefitinib (ZD1839, Iressa) in Non–Small Cell Lung Cancer Cell Lines Correlates with Gene Copy Number and EGFR Mutations but not EGFR Protein Levels
Open the PDF for Antitumor Activity of the Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Gefitinib (ZD1839, Iressa) in Non–Small Cell Lung Cancer Cell Lines Correlates with Gene Copy Number and EGFR Mutations but not EGFR Protein Levels in another window
Journal Articles

Selecting Lung Cancer Patients for Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by Immunohistochemistry and Fluorescence In situ Hybridization—Why, When, and How?

Free
Rafal Dziadziuszko, Fred R. Hirsch, Marileila Varella-Garcia, Paul A. Bunn, Jr.
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (14): 4409s–4415s.
https://doi.org/10.1158/1078-0432.CCR-06-0087
Published: 20 July 2006
View articletitled, Selecting Lung Cancer Patients for Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by Immunohistochemistry and Fluorescence In situ Hybridization—Why, When, and How?
Open the PDF for Selecting Lung Cancer Patients for Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by Immunohistochemistry and Fluorescence In situ Hybridization—Why, When, and How? in another window